The role of bisphosphonates in the management of metastatic prostate cancer

被引：3

作者：

M. Dror Michaelson

Matthew R. Smith

机构：

[1] Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA 02114

来源：

Current Oncology Reports | 2003年 / 5卷 / 3期

关键词：

Prostate Cancer; Bone Metastasis; Zoledronic Acid; Androgen Deprivation Therapy; Pamidronate;

D O I：

10.1007/s11912-003-0117-4

中图分类号：

学科分类号：

摘要：

Most men with advanced prostate cancer have primarily skeletal metastases, which are responsible for most of the morbidity and mortality of prostate cancer. Although bone lesions are osteoblastic in radiographic appearance, recent evidence has demonstrated that anti-osteoclast therapy with bisphosphonates reduces skeletal-related complications in hormone-refractory prostate cancer. This observation may be explained by the demonstration that osteoclast activity is greatly upregulated even in osteoblastic metastases. Furthermore, androgen deprivation therapy, the mainstay of treatment for advanced prostate cancer, leads to increased bone resorption and reduces bone mineral density. These effects can be ameliorated, and portentially completely prevented, by coadministnation of bisphosphonates. These findings may point to a role for bisphosphonates in men with prostate cancer even prior to the development of skeletal metastases. Determination of whether such early therapy ultimately results in delayed time to skeletal progression or in improved survival will require large randomized studies. Copyright © 2003 by Current Science Inc.

引用

页码：245 / 249

页数：4

共 30 条

[1]

Rogers M.J., Watts D.J., Russell R.G., Overview of bisphosphonates, Cancer, 80, SUPPL., pp. 1652-1660, (1997)

[2]

Watts N.B., Treatment of osteoporosis with bisphosphonates, Rheum. Dis. Clin. North Am., 27, pp. 197-214, (2001)

[3]

Berenson J.R., Lichtenstein A., Porter L., Et al., Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma, N. Engl. J. Med., 334, pp. 488-493, (1996)

[4]

Hortobagyi G.N., Theriault R.L., Porter L., Et al., Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases, N. Engl. J. Med., 335, pp. 1785-1791, (1996)

[5]

Paterson A.H., Adjuvant bisphosphonate therapy: The future, Semin. Oncol., 28, SUPPL. 11, pp. 81-85, (2001)

[6]

Diel I.J., Solomayer E.F., Bastert G., Bisphosphonates and the prevention of metastasis: First evidences from preclinical and clinical studies, Cancer, 88, SUPPL., pp. 3080-3088, (2000)

[7]

Clarke N.W., McClure J., George N.J., Morphometric evidence for bone resorption and replacement in prostate cancer, Br. J. Urol., 68, pp. 74-80, (1991)

[8]

Clarke N.W., McClure J., George N.J., Osteoblast function and osteomalacia in metastatic prostate cancer, Eur. Urol., 24, pp. 286-290, (1993)

[9]

Percival R.C., Urwin G.H., Harris S., Et al., Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption, Eur. J. Surg. Oncol., 13, pp. 41-49, (1987)

[10]

Garnero P., Buchs N., Zekri J., Et al., Markers of bone turnover for the management of patients with bone metastases from prostate cancer, Br. J. Cancer, 82, pp. 858-864, (2000)

← 1 2 3 →